AVERAGE VOLUME
5-Day
10-Day
30-Day
Aurobindo Pharma Ltd.
- NSE
- BSE
392.25
30.85 (8.54%)
16:03 | 27-03-2020
Volume
6,782,942
Mkt Cap (₹ Cr.)P/E (x)
Aurobindo Pharma Ltd.
ET 500
Rank 2019
87
ENGNew
- ENG - English
- HIN - हिन्दी
- GUJ - ગુજરાતી
- MAR - मराठी
- BEN - বাংলা
- KAN - ಕನ್ನಡ
- ORI - ଓଡିଆ
- TEL - తెలుగు
- TAM - தமிழ்
- NSE16:03 | 27-03-2020
- BSE12:00 | 27-03-2020
392.25
Today's Change
30.85 (8.54%)
Volume
6,782,942
Open
388.00
Prev. Close
361.40
Day's Trend
- Bid
- Mkt Cap (₹ Cr.)
- P/E (x)
- P/B (x)
- Div_ Yield (%)
- BETABETA1 Month3-Months6-Months1 Year3-Years
- Offer
- Face Value (₹)1.00
- EPS-TTM (Rs.)43.80
- BV/share (₹)237.11
- 52Wk L/H294.70/ 838.00
- Avg. Daily Volatility %Avg. Daily Volatility %1 Month3-Months6-Months1 Year3-Years
InsightsEvents|
Recos|
Updates|
News
Aurobindo Pharma Ltd Stock Price F & O Quotes
Maintain buy on Aurobindo Pharma, lower target price to Rs 530: Analyst| Recos
13 Mar, 2020, 03.11AM IST
Buy
Sell
Edelweiss Securities maintains ‘hold’ on Aurobindo Pharma, target price Rs 535| Recos
11 Feb, 2020, 02.58AM IST
Hold
Buy
Sell
Buy
Buy
Sell
Credit Suisse maintains neutral on Aurobindo Pharma, target price Rs 500| Recos
26 Nov, 2019, 03.36AM IST
Neutral
Buy
Buy
Buy
Sell
Sell
Buy
Buy
Buy
Sell
Buy
Buy
The week that was in 10 stocks: Bajaj Finserv tanks, Piramal shines; over 500 smallcaps erode wealth| News
29 Mar, 2020, 04.45AM IST
F&O: Nifty weekly chart shows promise, but overall structure still negative| News
27 Mar, 2020, 12.51PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011| Announcement
26 Mar,2020, 08:09PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011| Announcement
26 Mar,2020, 08:08PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011| Announcement
26 Mar,2020, 08:06PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011| Announcement
26 Mar,2020, 08:05PM IST
Share market update: Pharma shares advance; Piramal Enterprises zooms 30%| News
26 Mar, 2020, 06.28AM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011| Announcement
25 Mar,2020, 03:59PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011| Announcement
23 Mar,2020, 05:21PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011| Announcement
20 Mar,2020, 05:42PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
17 Mar,2020, 05:37PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
17 Mar,2020, 02:13PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
17 Mar,2020, 02:11PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
17 Mar,2020, 02:09PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
17 Mar,2020, 02:09PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
17 Mar,2020, 02:07PM IST
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
16 Mar,2020, 06:11PM IST
Aurobindo Pharma gets EIR with VAI status from USFDA for Hyderabad facility| News
26 Feb, 2020, 06.41AM IST
Is specialty business ‘a go or a no-go’ segment for pharma companies?| News
26 Feb, 2020, 06.00AM IST
Aurobindo Pharma Ltd.Update On US FDA Inspection At Our Unit VIII - Reg.,| Announcement
26 Feb,2020, 09:05AM IST
Aurobindo Pharma Ltd.Announcement under Regulation 30 (LODR)-Earnings Call Transcript| Announcement
24 Feb,2020, 10:44AM IST
Aurobindo Pharma tumbles 18% on USFDA's U-turn; here's what analysts say| News
24 Feb, 2020, 11.35AM IST
Share market update: Hindalco, Aurobindo Pharma among top losers on BSE| News
24 Feb, 2020, 03.59AM IST
Aurobindo Pharma Ltd.Further update on US FDA Inspection at our Unit IV| Announcement
21 Feb,2020, 04:12PM IST
Aurobindo Pharma Ltd.Update On US FDA Inspection At Our Unit IV - Reg.,| Announcement
19 Feb,2020, 08:46AM IST
Aurobindo Pharma Ltd. Share Price Updates
Aurobindo Pharma Ltd. share price
up by 8.54% from its previous close of Rs 361.40. Aurobindo Pharma Ltd. stock last traded price is 392.25
Aurobindo Pharma Ltd. Share Price
Value
Today/Current/Last
392.25
Previous Day
361.40
Aurobindo Pharma Ltd. Quarterly Results
Yesconsolidate
Loading...Dec 2019
% Chg (Quarterly)
% Chg (Yearly)
Peer Range
Trend
Last 12 Quarters Trend
Sales
5,799.44
5.10
12.06
0.00
8154.85
Other Operating Income
95.56
16.25
1.22
0.00
136.45
Operating Profit
1,208.04
5.95
11.20
-27.67
2683.77
Other Income
30.93
50.00
-51.56
-0.05
119.88
EBITDA
1,238.97
6.73
7.71
-27.67
2683.77
Interest
37.11
-9.36
-22.12
-0.10
111.00
Depreciation
250.13
2.80
53.34
0.00
546.99
Tax
232.86
3.78
13.71
-9.24
767.02
Net Profit
705.45
10.25
-0.95
-835.00
1019.38
EPS (₹)
12.04
10.26
-0.91
-94.30
31.95
View Detailed FinancialsProfit and LossCash FlowsBalance SheetQuarterly ResultsHalf Year resultsCapital Structure
Aurobindo Pharma Ltd ResutlsAurobindo Pharma Q1 ResultsAurobindo Pharma Q2 ResultsAurobindo Pharma Q3 ResultsAurobindo Pharma Q4 Results
Aurobindo Pharma Ltd Share Price
Companies
LTP
Intraday
1W %
1M %
1 QTR %
1 YR %
3 YR %
5 Yr %
Trend -
D|M|Y
Top Loser for the period amongst the peers
Top Gainer for the period amongst the peers
Aurobindo Pharma Ltd Risk Return Comparison
with peersNewAurobindo Pharma Ltd Financial Comparison
with peersManagement Efficiency
Aurobindo Pharma Ltd
peer Average
Peer Range
Trend
Return on Equity (%)
17.02
8.97
-99.01
47.57
Return on Assets (%)
9.06
5.58
-27.48
26.25
Return on capital Employed (%)
10.35
5.73
-130.86
23.02
Fixed Assets Turnover (x)
1.06
-1.83
-193.68
2.83
Profitability and Growth
Gross Profit Margin (%)
16.78
-8.24
-980.00
34.42
Operating Profit Margin(%)
20.20
0.75
-896.19
37.94
Net Profit margin (%)
12.08
1.93
-461.80
94.28
Financial Strength
Liquidity
Quick Ratio (x)
1.47
1.62
0.08
9.50
Current Ratio (x)
2.75
2.36
0.21
9.50
Cash ratio (x)
0.34
0.22
-0.52
1.40
Solvency
Debt Equity Ratio (x)
0.01
0.29
0.00
2.65
Coverage Ratios
Cash flows to long term debt (x)
2.17
3.92
0.00
45.52
Better performer than its peers on this ratioAverage performer than its peers on this ratioUnderperformer than its peers on this ratio
Aurobindo Pharma Ltd Share Holding as on 31-12-2019
| Category | No. of shares | Percentage |
|---|---|---|
| Promoters | 285,925,934 | 48.80 |
| ForeignInstitutions | 125,535,961 | 21.42 |
| Others | 24,469,248 | 4.18 |
| NBanksMutualFunds | 74,862,242 | 12.78 |
| GeneralPublic | 54,811,031 | 9.35 |
| FinancialInstitutions | 2,334,193 | 0.40 |
| ForeignPromoter | 18,000,000 | 3.07 |
MF Ownership Of Aurobindo Pharma Ltd. Shares
Fund Name
Category
No. of shares
% Change in Shares (MOM basis)
% of AUM
Amount Invested (in ₹ Cr)
HDFC Balanced Advantage Direct-GPortfolio as on 29-02-2020
Hybrid: Dynamic Asset Allocation
13797328
32.63%
1.7%
697.45
HDFC Hybrid Equity Direct-GPortfolio as on 29-02-2020
Hybrid: Aggressive Hybrid
7361000
0.00%
1.97%
372.10
HDFC Mid-Cap Opportunities Direct-GPortfolio as on 29-02-2020
Equity: Mid Cap
4627400
12.11%
1.03%
233.92
Liquid, Ultra Short Term funds and FMPs are not taken into account.
More SchemesAbout Aurobindo Pharma Ltd.
Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 22986.37 Crore) operating in Pharmaceuticals sector.
Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 11922.63 Crore to Sales Value (97.26 % of Total Sales), Export Incentives which contributed Rs 303.72 Crore to Sales Value (2.47 % of Total Sales), Sale of services which contributed Rs 16.07 Crore to Sales Value (0.13 % of Total Sales) and Scrap which contributed Rs 15.47 Crore to Sales Value (0.12 % of Total Sales)for the year ending 31-Mar-2019.
For the quarter ended 31-12-2019, the company has reported a Consolidated sales of Rs 5799.44 Crore, up 5.10 % from last quarter Sales of Rs 5518.27 Crore and up 12.06 % from last year same quarter Sales of Rs 5175.26 Crore Company has reported net profit after tax of Rs 705.95 Crore in latest quarter.
The company’s top management includes Dr.M Sivakumaran, Mr.P V Ramprasad Reddy, Mr.P Sarath Chandra Reddy, Mr.N Govindarajan, Mr.M Sitarama Murthy, Mr.M Madan Mohan Reddy, Mr.K Ragunathan, Mr.K Nithyananda Reddy, Dr.(Mrs.)Avnit Bimal Singh, Mrs.Savita Mahajan. Company has BSR & Associates LLP as its auditors As on 31-12-2019, the company has a total of 585,938,609 shares outstanding.
View DetailsChairman's SpeechCompany HistoryDirectors ReportBackground informationCompany ManagementListing InformationFinished ProductsBoard MeetingsAGM/EGM
Close X
WatchlistPortfolio
Current Price>: 2389.88
Set Alert
Loadingdata